1. Home
  2. IKT vs TBI Comparison

IKT vs TBI Comparison

Compare IKT & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$1.97

Market Cap

274.9M

Sector

Health Care

ML Signal

N/A

Logo TrueBlue Inc.

TBI

TrueBlue Inc.

N/A

Current Price

$8.92

Market Cap

311.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
IKT
TBI
Founded
2008
1985
Country
United States
United States
Employees
35
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
274.9M
311.4M
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
IKT
TBI
Price
$1.97
$8.92
Analyst Decision
Strong Buy
Buy
Analyst Count
9
2
Target Price
$6.00
★ $9.75
AVG Volume (30 Days)
★ 424.9K
220.6K
Earning Date
11-13-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
57.76
★ 61.39
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$8.10
Revenue Next Year
$33.33
$3.33
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$3.18
52 Week High
$2.61
$11.03

Technical Indicators

Market Signals
Indicator
IKT
TBI
Relative Strength Index (RSI) 34.43 42.62
Support Level $1.93 $8.63
Resistance Level $2.13 $8.90
Average True Range (ATR) 0.10 0.38
MACD -0.01 -0.04
Stochastic Oscillator 16.84 5.17

Price Performance

Historical Comparison
IKT
TBI

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.

Share on Social Networks: